These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 6019354)

  • 41. Insulin response to glucagon with or without tolbutamide in normal and diabetic subjects.
    Chiba M; Ohneda A; Sakai T; Goto Y
    Tohoku J Exp Med; 1982 Feb; 136(2):169-75. PubMed ID: 7041329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum insulin, glucose, and lipid levels among mild diabetics in relation to incidence of vascular complications.
    Elkeles RS; Lowy C; Wyllie AD; Young JL; Fraser TR
    Lancet; 1971 May; 1(7705):880-3. PubMed ID: 4102026
    [No Abstract]   [Full Text] [Related]  

  • 43. Response of blood sugar, pyruvate and serum ILA (rat hemidiaphragm) to intravenous sodium tolbutamide in normal and diabetic subjects.
    Rastogi GK
    Indian J Med Res; 1970 Apr; 58(4):438-43. PubMed ID: 5506667
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacological intervention: the antidiabetic approach.
    Melander A
    Eur J Clin Invest; 1998 Sep; 28 Suppl 2():23-5; discussion 25-6. PubMed ID: 9777324
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal.
    Tsalikian E; Dunphy TW; Bohannon NV; Lorenzi M; Gerich JE; Forsham PH; Kane JP; Karam JH
    Diabetes; 1977 Apr; 26(4):314-21. PubMed ID: 849812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucose and insulin secretory response patterns following diet and tolazamide therapy in diabetes.
    Turtle JR
    Br Med J; 1970 Sep; 3(5723):606-10. PubMed ID: 5470087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Estimation of insulin efficacy in obesity by the response of blood insulin and glucose to intravenous tolbutamide].
    Vague P; Depieds R; Boeuf G; Leroy C; Perrimond D; Codaccioni JL; Vague J
    Ann Endocrinol (Paris); 1966; 27(6):820-9. PubMed ID: 5973133
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical experience with the oral antidiabetic compound, tolazamide.
    McKendry JB; Gfeller KF
    Can Med Assoc J; 1967 Mar; 96(9):531-5. PubMed ID: 6019353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatic effect of sulfonylureas.
    Marshall A; Gingerich RL; Wright PH
    Metabolism; 1970 Dec; 19(12):1046-52. PubMed ID: 5492043
    [No Abstract]   [Full Text] [Related]  

  • 50. Plasma insulin activity in human diabetes during hypoglycemic response to tolbutamide and indole-3-acetic acid.
    SELTZER HS; SMITH WL
    Proc Soc Exp Biol Med; 1959 Jan; 100(1):171-4. PubMed ID: 13634074
    [No Abstract]   [Full Text] [Related]  

  • 51. Glucose and insulin after diet and tolazamide treatment.
    Sheldon J
    Br Med J; 1970 Oct; 4(5729):246. PubMed ID: 5472796
    [No Abstract]   [Full Text] [Related]  

  • 52. The effect of food on the bioavailability and pharmacodynamics of tolbutamide in diabetic patients.
    Antal EJ; Gillespie WR; Phillips JP; Albert KS
    Eur J Clin Pharmacol; 1982; 22(5):459-62. PubMed ID: 6749526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of oral antidiabetics on the anaphylactoid reaction.
    Wellinger K; Koltai M
    Acta Physiol Acad Sci Hung; 1981; 58(4):317-9. PubMed ID: 6182744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral glucose tolerance and related factors in a normal population sample. I. Blood sugar, plasma insulin, glyceride, and cholesterol measurements and the effects of age and sex.
    Boyns DR; Crossley JN; Abrams ME; Jarrett RJ; Keen H
    Br Med J; 1969 Mar; 1(5644):595-8. PubMed ID: 5766122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dynamics of tolbutamide, glucose, and insulin interrelationships following varying doses of intravenous tolbutamide in normal subjects.
    Ganda OP; Kahn CB; Soeldner JS; Gleason RE
    Diabetes; 1975 Apr; 24(4):354-67. PubMed ID: 1132601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The behaviour of the serum insulin level in non obese adult diabetics after intravenous glucose, tolbutamide and glucagon].
    Lawecki J; Rogala H; Czyzyk A; Kowalski H
    Acta Diabetol Lat; 1970; 7(3):407-20. PubMed ID: 5515384
    [No Abstract]   [Full Text] [Related]  

  • 57. PHENFORMIN, SERUM LIPIDS AND DIABETES MELLITUS.
    SCHWARTZ MJ; MIRSKY S; SCHAEFER LE
    Lancet; 1965 May; 1(7392):959. PubMed ID: 14275725
    [No Abstract]   [Full Text] [Related]  

  • 58. Adjuvant therapy with tolazamide and insulin improves metabolic control in type I diabetes mellitus.
    Kabadi UM
    Diabetes Care; 1985; 8(5):440-6. PubMed ID: 3902422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LIMITATIONS IN THE USE OF ORAL HYPOGLYCEMIC AGENTS IN JUVENILE PATIENTS WITH DIABETES.
    KAYE R; DAVIDSON MH
    J Pediatr; 1965 May; 66():844-56. PubMed ID: 14279844
    [No Abstract]   [Full Text] [Related]  

  • 60. A case of maturity-onset diabetes mellitus resistant to insulin but responsive to tolbutamide.
    Rendell M; Slevin D; Meltz G; Simpson J; Barquet A
    Ann Intern Med; 1979 Feb; 90(2):195-7. PubMed ID: 443652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.